BR112019007927A2 - conjugados de polimixina ? oligômeros de alginato - Google Patents

conjugados de polimixina ? oligômeros de alginato

Info

Publication number
BR112019007927A2
BR112019007927A2 BR112019007927A BR112019007927A BR112019007927A2 BR 112019007927 A2 BR112019007927 A2 BR 112019007927A2 BR 112019007927 A BR112019007927 A BR 112019007927A BR 112019007927 A BR112019007927 A BR 112019007927A BR 112019007927 A2 BR112019007927 A2 BR 112019007927A2
Authority
BR
Brazil
Prior art keywords
conjugate
polymyxin
alginate oligomers
alginate oligomer
bacterial
Prior art date
Application number
BR112019007927A
Other languages
English (en)
Portuguese (pt)
Inventor
Dessen Arne
William Thomas David
Ferguson Elaine
Rye Philip
Original Assignee
Algipharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1617860.0A external-priority patent/GB201617860D0/en
Priority claimed from GBGB1714710.9A external-priority patent/GB201714710D0/en
Application filed by Algipharma As filed Critical Algipharma As
Publication of BR112019007927A2 publication Critical patent/BR112019007927A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
BR112019007927A 2016-10-21 2017-10-20 conjugados de polimixina ? oligômeros de alginato BR112019007927A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1617860.0A GB201617860D0 (en) 2016-10-21 2016-10-21 Polymyxin-alginate oligomer conjugates
GBGB1714710.9A GB201714710D0 (en) 2017-09-13 2017-09-13 Polymyxin-alginate oligomer conjugates
PCT/EP2017/076927 WO2018073449A1 (en) 2016-10-21 2017-10-20 Polymyxin-alginate oligomer conjugates

Publications (1)

Publication Number Publication Date
BR112019007927A2 true BR112019007927A2 (pt) 2019-07-02

Family

ID=60186268

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019007927A BR112019007927A2 (pt) 2016-10-21 2017-10-20 conjugados de polimixina ? oligômeros de alginato

Country Status (13)

Country Link
US (1) US20190328833A1 (cg-RX-API-DMAC7.html)
EP (1) EP3528830B1 (cg-RX-API-DMAC7.html)
JP (1) JP2020503253A (cg-RX-API-DMAC7.html)
KR (1) KR20190072579A (cg-RX-API-DMAC7.html)
CN (1) CN109843315A (cg-RX-API-DMAC7.html)
AU (1) AU2017345295A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019007927A2 (cg-RX-API-DMAC7.html)
CA (1) CA3040795A1 (cg-RX-API-DMAC7.html)
DK (1) DK3528830T3 (cg-RX-API-DMAC7.html)
ES (1) ES2933983T3 (cg-RX-API-DMAC7.html)
FI (1) FI3528830T3 (cg-RX-API-DMAC7.html)
RU (1) RU2019109719A (cg-RX-API-DMAC7.html)
WO (1) WO2018073449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7683941B2 (ja) * 2019-12-14 2025-05-27 チャウダリ,マヌ 多臓器毒性を低減するための多塩基性薬剤の調製
WO2021150792A1 (en) * 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
US12037631B2 (en) * 2020-10-06 2024-07-16 City University Of Hong Kong System and method for detecting a target enzyme
CN113081956A (zh) * 2021-04-12 2021-07-09 青岛大学附属医院 一种氧化海藻酸钠改性的那他霉素滴眼液及其制备方法
CN113069556B (zh) * 2021-04-12 2022-04-08 青岛大学附属医院 一种枝接那他霉素的氧化海藻酸纤维膜及其制备方法
WO2023001224A1 (en) * 2021-07-21 2023-01-26 Shanghai Micurx Pharmaceutical Co., Ltd. Novel compounds and compositions for targeted therapy of renal cancers
WO2023001223A1 (en) * 2021-07-21 2023-01-26 Shanghai Micurx Pharmaceutical Co., Ltd. Compounds and compositions for targeted therapy of renal diseases
CN114009731B (zh) * 2021-11-05 2024-01-02 恒枫食品科技有限公司 一种茶风味基料及其制备方法、应用
CN114752535A (zh) * 2022-05-16 2022-07-15 北京昊峰节能环保科技有限公司 一种总石油烃污染地下水生物修复剂及其制备方法与应用
CN121948713B (zh) * 2026-04-03 2026-07-17 亚太森博(山东)浆纸有限公司 一种硫酸盐法制浆中dcm控制剂引发二沉池浮泥的处理方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB976301A (en) * 1960-10-27 1964-11-25 Calmic Ltd Preparation and use of alginates
DE69012747T2 (de) * 1989-11-15 1995-03-16 Sandoz Ag Polymyxinkonjugate.
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
RU2527894C2 (ru) * 2007-11-27 2014-09-10 Альгифарма ИПР АС Использование альгинатных олигомеров в борьбе с биопленками
RU2582938C2 (ru) * 2009-06-03 2016-04-27 АльгиФарма АС Альгинатные олигомеры для применения в преодолении множественной лекарственной устойчивости у бактерий

Also Published As

Publication number Publication date
WO2018073449A1 (en) 2018-04-26
RU2019109719A (ru) 2020-11-24
CA3040795A1 (en) 2018-04-26
EP3528830A1 (en) 2019-08-28
RU2019109719A3 (cg-RX-API-DMAC7.html) 2021-02-20
FI3528830T3 (fi) 2023-01-13
KR20190072579A (ko) 2019-06-25
EP3528830B1 (en) 2022-10-05
JP2020503253A (ja) 2020-01-30
AU2017345295A1 (en) 2019-05-02
CN109843315A (zh) 2019-06-04
ES2933983T3 (es) 2023-02-15
DK3528830T3 (da) 2022-12-19
US20190328833A1 (en) 2019-10-31

Similar Documents

Publication Publication Date Title
BR112019007928A2 (pt) conjugados de bacitracina-oligômero de alginato
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
ZA202210065B (en) Interleukin-21 muteins and methods of treatment
CY1121416T1 (el) Yποκατεστημενοι νουκλεοζιτες, νουκλεοτιδια και αναλογα αυτων
CY1120796T1 (el) Συνδυασμος φαινοξυβενζαμινης και πολυμυξινης ε για την θεραπευτικη αντιμετωπιση των μικροβιακων λοιμωξεων
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
MA37206B1 (fr) Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2019136180A3 (en) Heteroduplex nucleic acid molecules and uses thereof
BR112018006016A2 (pt) intermediário de ligante-droga, compostos conjugados de anticorpo-droga, composições farmacêuticas, métodos para tratar câncer, método de produção de um composto conjugado e conjugado de anticorpo-droga
BR112016004023A2 (pt) Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
BR112019000453A2 (pt) combinação de ceftibuteno e ácido clavulânico para uso no tratamento de infecções bacterianas
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
WO2017191130A3 (en) Arginase inhibitors and their therapeutic applications
BR112017005736A2 (pt) macrociclos peptidomiméticos e formulações dos mesmos
NO20090251L (no) Camptotecinderivater med antitumoraktivitet
MX2020011100A (es) Compuestos, composiciones farmaceuticas y metodos de uso de agonistas de ppar.
BR112017011478A2 (pt) composto de conjugado anticorpo-antibiótico, conjugado anticorpo-antibiótico, composição farmacêutica, métodos de tratamento de uma infecção bacteriana e para exterminar staph aureus, processo para a preparação do composto, kit e intermediário antibiótico-ligante
EA201891419A1 (ru) Пептид-олигонуклеотидные конъюгаты
CN110382500A (zh) 用于ido和tdo双重抑制剂的脲类化合物
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
BR112018010759A2 (pt) composições farmacêuticas, processo para preparação de composição farmacêutica, e, método de tratamento curativo ou profilático
BR112018003181A2 (pt) composto, composição, e, método para tratar infecção por hiv
BR112021018372A2 (pt) Composto acilaminopirrolo-piridona, método para preparar o referido composto, composição farmacêutica e uso do mesmo
BR112018071108A2 (pt) antígenos e anticorpos de chagas e composições, métodos e usos dos mesmos

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2745 DE 15-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.